| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management named NVIDIA Corporation (NASDAQ:NVDA) as her final trade.
NVIDIA recently announced a 10-for-1 stock split. The semiconductor giant revealed this decision during its recent quarterly earnings report. The split-adjusted trading commenced on Monday, June 10.
Jim Lebenthal of Cerity Partners picked Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which is a biopharmaceutical company.
On Friday, Vertex revealed positive long-term data on CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress.
Don't forget to check out our premarket coverage here
Kevin Simpson of Capital Wealth Planning named ConocoPhillips (NYSE:COP), saying the acquisition of Marathon Oil Corporation (NYSE:MRO) will be aggregate over time.
On Friday, BofA Securities analyst Kalei Akamine reinstated ConocoPhillips with a Buy rating and announced a price target of $147.
Rob Sechan of NewEdge Wealth said AbbVie Inc. (NYSE:ABBV) has an attractive valuation, wonderful pipeline and a great yield.
On June 6, AbbVie released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (Elahere) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9%.
Price Action:
Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 3% Dividend Yields
Image generated using artificial intelligence via Midjourney.
